Search

Your search keyword '"Tortorella, Carla"' showing total 410 results

Search Constraints

Start Over You searched for: Author "Tortorella, Carla" Remove constraint Author: "Tortorella, Carla"
410 results on '"Tortorella, Carla"'

Search Results

1. Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project

5. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

6. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose

10. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

11. Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience

12. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

15. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

16. Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay

18. Radiological Reporting Systems in Multiple Sclerosis.

20. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria

22. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis

23. Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study

24. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

25. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

27. Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study

28. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

30. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study

33. Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs

34. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose

35. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study

36. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study

37. Stopping disease-modifying treatments in multiple sclerosis: a meta-analysis with meta-regression

38. “Better explanations” in multiple sclerosis diagnostic workup: A 3-year longitudinal study

40. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies

41. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

42. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks

43. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks

45. Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis

47. Shift of multiple sclerosis onset towards older age

50. Digital work engagement among Italian neurologists

Catalog

Books, media, physical & digital resources